News | Computed Tomography (CT) | November 26, 2022

Collaboration agreements announced to expand offerings on new medical imaging platform Calantic Digital Solutions across key disease area

The new MEDRAD  Centargo CT Injection System minimises your injector touch time by automating manual processes, helping you to focus on what matters most in every CT scan – the patient.

November 26, 2022 — As international leaders in the field of Imaging gather for the 2022 Radiological Society of North America (RSNA) Annual Meeting, Bayer Radiology, a leader in diagnostic imaging, will showcase its portfolio of products and solutions intended to address today's most pressing issues facing the field of Radiology. In addition, Bayer will present new scientific data on an investigational contrast agent. The 2022 RSNA will take place from November 27 to December 1 in Chicago.

Bayer’s focus areas at RSNA represent the company’s commitment to help address staff shortages with solutions that focus on patient throughput and workflow efficiencies to drive automation and standardization, scientific investment for the benefit of patients and their physicians and leveraging the vast potential of data and AI.

Next generation CT technology and workflow solutions highlight integrated offerings that manage complexity and deliver accurate diagnostic information more efficiently.

Bayer’s introduction of Injector Management* software enables consistency and standardization by offering the ability to share common protocols through connected injectors. *not yet commercially available.

Bayer will showcase its next generation CT technology, MEDRAD Centargo CT Injection System (Centargo) at RSNA (Centargo is 510(k) pending and not available for sale in the US. The latest addition to Bayer's CT portfolio is designed to drive workflow efficiency with design features that work in conjunction with Bayer's portfolio of products to bring innovative technology to the imaging suite and introduce new technology in the areas of patient set-up.

Expanding AI offerings on Calantic Digital Solutions

Bayer is also announcing collaboration agreements with app developers Quantib, ClariPi, and EXINI Diagnostics to strategically expand the offering on its medical imaging platform Calantic Digital Solutions. The platform, which was launched recently, delivers access to applications, including those enabled by AI, for medical imaging. With these new collaboration agreements, Bayer is broadening the already available options for thoracic and neurological diseases on the platform by including tools which aim to aid in breast and prostate imaging.

Introducing app accelerator program Calantic SPARK

In addition, Bayer has recently launched Calantic SPARK, a new accelerator program for medical imaging app developers to further foster innovation in radiology AI. The program will initially focus on North America and Europe and is planned to be expanded to other regions including Asia-Pacific. Bayer offers a targeted program intended to accelerate market readiness for early-stage projects and offerings, providing advice spanning medical, regulatory, reimbursement expertise, and market access. Tapping the thriving start-up ecosystem of AI in medical imaging, Calantic SPARK provides program participants with a potential pathway towards commercialization and distribution through Calantic Digital Solutions. Details about Calantic SPARK will be presented at Bayer’s booth as well as the AI Showcase Theatre at the RSNA.

Corporate Symposiums

The Role of a High Relaxivity Contrast Agent in CNS and MRA Imaging
Monday, November 28, 9:30 a.m., (CT)
Room: S102AB

From AI Conception to Validation; The role of AI Orchestration Platforms
Al Showcase Theater Presentation
Monday, November 28, 1:00 p.m., (CT)
Room: S102AB

Collaboration Sparks, How Bayer is Engaging with the Startup Ecosystem.
Monday November 28, 11:00 a.m., (CT)
Room: AI Theatre

Techniques and Considerations in Liver Imaging.
Tuesday, November 29, 10:30 a.m., (CT)
Virtual Product Theatre

Driving AI Innovation to Assess Reimbursable Apps
Wednesday, November 30, 3:00 p.m., (CT)
Innovation Theatre

Scientific Presentation on an investigational new molecular entity

Bayer will be presenting results of early clinical trial data on an investigational contrast agent. Gadoquatrane is a gadolinium-based contrast agent in Phase II of development. The study investigated the pharmacokinetics including excretion pathways, safety and tolerability of gadoquatrane in healthy volunteers.

  • Session Number: R5A-SPNR; Dec 1; 12:15 - 12:45 p.m., (CT)

For more information: www.bayer.com

Find more RSNA22 coverage here 


Related Content

News | Cardiac Imaging

September 21, 2023 — Declines in cardiovascular procedure volumes observed early in the COVID-19 pandemic greatly ...

Time September 21, 2023
arrow
News | Artificial Intelligence

September 20, 2023 — Medical imaging artificial intelligence (AI) company Annalise.ai has announced that the results ...

Time September 20, 2023
arrow
Sponsored Content | Case Study | Radiology Imaging | By Tim Hodson

In June, the Philips Radiology Experience Tour hit the road to provide healthcare professionals with an opportunity to ...

Time September 19, 2023
arrow
News | Computed Tomography (CT)

September 19, 2023 — An advanced CT test can identify individuals with stable angina at a reduced risk of three-year ...

Time September 19, 2023
arrow
News | Ultrasound Imaging

September 15, 2023 — Contrast enhanced ultrasound (CEUS) is underutilized in the United States, and reduced access to ...

Time September 15, 2023
arrow
News | Mobile C-Arms

September 14, 2023 — Royal Philips, a global leader in health technology, today announced the launch of Philips Image ...

Time September 14, 2023
arrow
News | FDA

September 13, 2023 — Annalise.ai, a leader in AI-powered medical imaging solutions, announced the receipt of 510(k) ...

Time September 13, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

September 8, 2023 — A simple, noninvasive contrast enhanced ultrasound (CEUS) scan is an ideal tool for resolving ...

Time September 08, 2023
arrow
News | Ultrasound Imaging

September 8, 2023 — When diagnosing and treating cancer patients, the dynamics of blood flow to and from a suspected ...

Time September 08, 2023
arrow
News | Mammography

September 5, 2023 — Using a standardized assessment, researchers in the UK compared the performance of a commercially ...

Time September 05, 2023
arrow
Subscribe Now